Scilex Holding (SCLXW) Income from Continuing Operations (2020 - 2026)
Scilex Holding (SCLXW) recorded quarterly Income from Continuing Operations of 45650000.0 in Q1 2026, up 0.99% quarter-over-quarter from 46105000.0 in Q4 2025, and down 75.04% on a YoY basis from 182880491.55 in Q1 2025.
Scilex Holding (SCLXW) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Scilex Holding's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 45650000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 75.04% year-over-year to 45650000.0; the TTM figure through Mar 2026 stood at 393623000.0 (down 428.28% YoY), while the FY2025 annual figure was 374053000.0, down 413.76% from the prior year.
- Income from Continuing Operations was 45650000.0 for Q1 2026 at Scilex Holding, up from 46105000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 21501000.0 in Q3 2022 to a low of 257820000.0 in Q3 2025.
- Historically, Income from Continuing Operations has averaged 37070882.35 across 5 years, with a median of 26080000.0 in 2025.
- Biggest YoY gain for Income from Continuing Operations was 7736.6% in 2022; the steepest drop was 10688.09% in 2022.
- A 5-year view of Income from Continuing Operations shows it stood at 17884000.0 in 2022, then declined by 19.66% to 21400000.0 in 2023, then jumped by 69.81% to 6460000.0 in 2024, then plunged by 613.7% to 46105000.0 in 2025, then increased by 0.99% to 45650000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 45650000.0 (Q1 2026), 46105000.0 (Q4 2025), and 257820000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 3.30 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 7.40 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 5.24 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 697.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 2.71 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 2.68 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn | -45.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.65 Mn |
| Dec 31, 2025 | -46.11 Mn |
| Sep 30, 2025 | -257.82 Mn |
| Jun 30, 2025 | -44.05 Mn |
| Mar 31, 2025 | -26.08 Mn |
| Dec 31, 2024 | -6.46 Mn |
| Sep 30, 2024 | -4.39 Mn |
| Jun 30, 2024 | -37.58 Mn |
| Mar 31, 2024 | -24.38 Mn |
| Dec 31, 2023 | -21.40 Mn |
| Sep 30, 2023 | -35.53 Mn |
| Jun 30, 2023 | -26.65 Mn |
| Mar 31, 2023 | -30.75 Mn |
| Dec 31, 2022 | -17.88 Mn |
| Sep 30, 2022 | 21.50 Mn |
| Jun 30, 2022 | -17.84 Mn |
| Mar 31, 2022 | -9.14 Mn |
| Dec 31, 2021 | -35.26 Mn |
| Sep 30, 2021 | -281,552.00 |
| Jun 30, 2021 | -165,349.00 |